Europe Vaccines Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031

The Europe Vaccines Market size is expected to reach US$ 35,815.1 Million by 2031 from US$ 24,528.3 Million in 2024. The market is estimated to record a CAGR of 5.6% from 2025 to 2031.

Executive Summary and Europe Vaccines Market Analysis:

As per the Annual Epidemiological Report published by European Centre for Disease Prevention and Control (ECDC) in April 2025, a total of 35,212 measles cases were reported across the European Union (EU)/European Economic Area (EEA) in 2024, representing a 10-fold increase from the 3,973 cases reported in 2023. Additionally, the reported cases followed a seasonal pattern, a notable change after the period from 2021 to 2023, when the typical pattern was not observed. Measles activity had already started to rise in the region in 2023 following a period of unusually low incidence during 2020-2022, which coincided with the COVID-19 pandemic.
As per the ECDC recommendations, to prevent measles outbreaks, at least 95% of the eligible population should receive two doses of the measles, mumps, and rubella (MMR) vaccine. However, the MMR monthly report published by ECDC in July 2025 indicated that only Hungary, Malta, Portugal, and Slovakia met this target in the EU/EEA. Such increasing prevalence of infections fuels the demand for vaccines for disease prevention.

Europe Vaccines Market: Strategic Insights

Europe Vaccines Market Segmentation Analysis:

• By Type, the Europe Vaccines Market is segmented into Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated Vaccines segment held the largest share of the market in 2024.
• By Indication, the Europe Vaccines Market is segmented into HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other. The HPV segment held the largest share of the market in 2024.
• By Route of Administration, the Europe Vaccines Market is segmented into Injection, Oral, and Other. The injection segment held the largest share of the market in 2024.
• By Age Group, the Europe Vaccines Market is segmented into Pediatric and Adult. The pediatric segment held the largest share of the market in 2024.

Europe Vaccines Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Vaccines Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Europe Vaccines Market Outlook

The vaccine industry is currently experiencing a transformative phase, with combination and therapeutic vaccines emerging as the most promising opportunities for manufacturers. Innovations in these vaccines not only address evolving public health challenges but also provide significant commercial and operational advantages.
Combination vaccines are formulations designed to protect against multiple diseases in a single shot. Traditionally used in pediatric care, as seen with vaccines like MMR (measles, mumps, rubella) and DTP (diphtheria, tetanus, pertussis), combination vaccines are now expanding their reach to adult and elderly populations. This is particularly relevant for respiratory illnesses such as influenza, COVID-19, and Respiratory Syncytial Virus (RSV). Combination vaccines can greatly improve immunization rates, resulting in a quicker and more extensive reduction in disease burden. They are especially important as new vaccines for diseases such as dengue, typhoid, RSV, and tuberculosis are being developed.

According to Gavi, by 2030, combination vaccines will provide protection against 30 infections with fewer doses. Major pharmaceutical companies, including Moderna, Pfizer/BioNTech, Novavax, Sanofi, GSK, and AstraZeneca, are developing combination vaccines for COVID-19, influenza, and RSV. These products are anticipated to transform seasonal immunization strategies and enhance uptake among adults and elderly populations. Additionally, therapeutic vaccines are designed not to prevent diseases but to treat existing conditions, which can include chronic infections, cancers, and allergies. This approach represents a new frontier in vaccine technology, utilizing advancements in mRNA, viral vectors, and personalized medicine. For instance, cancer vaccines aim to stimulate the immune system to recognize and attack tumor cells. Additionally, some vaccines are being developed for chronic infections such as hepatitis B and HIV.

As of 2024, the US Food and Drug Administration (FDA) has approved three therapeutic vaccines: Sipuleucel-T for advanced prostate cancer, Bacillus Calmette-Guerin for high-risk, non-muscle-invasive bladder cancer, and Talimogene laherparepvec for melanoma. As research progresses, therapeutic vaccines are expected to become a significant segment within the broader vaccine market, addressing unmet medical needs and expanding the potential customer base. Several companies are currently under trial for therapeutic cancer vaccines aimed at cancers and other chronic diseases. These vaccines are designed to enhance the body's immune response against cancer cells and are often used alongside other treatment modalities. TherVacB is a novel therapeutic vaccine designed to combat chronic hepatitis B and entered its first clinical trial in February 2024. The Phase Ia clinical trial was conducted at the Division of Infectious Diseases and Tropical Medicine at LMU University Hospital in Munich, with the University Medical Center Hamburg-Eppendorf serving as the sponsor. This trial will investigate the safety and immunogenicity of the new vaccine candidate in healthy volunteers.

Both combination and therapeutic vaccines align with global health priorities by improving access, reducing the disease burden, and addressing complex health challenges. Their development benefits from significant public and private investment, collaborative partnerships, and ongoing advancements in biotechnology.
Therefore, the development of combination and therapeutic vaccines presents substantial opportunities for vaccine manufacturers to grow, innovate, and create a meaningful impact. These vaccines simplify immunization, expand their applications, and address both preventive and therapeutic health needs worldwide.

Europe Vaccines Market Country Insights

By country, The Europe Vaccines Market is segmented into Germany, the United Kingdom, France, Italy, Spain, and the Rest of Europe. Germany held the largest share in 2024.

Germany is a prominent research hub, with numerous pharmaceutical and biotechnology companies dedicated to developing therapies for conditions such as cancer, cardiovascular disorders, metabolic diseases, as well as applications in drug formulation and development. The presence of research institutions and leading vaccine manufacturers is driving growth in the German vaccines market. Germany's DZIF (German Center for Infection Research) launched EVH, a major EU-wide public-private partnership. It focuses on developing pandemic-prototype vaccines, scalable technologies, and strengthening pandemic preparedness across Europe. The project has secured ~US$ 120.14 million in funding over four years. Of this amount, ~US$ 24.74 million will be allocated to German institutions through the DZIF. This funding is part of the EU4Health program, which was launched in response to the pandemic and aims to enhance the EU's preparedness for future crises.
In July 2023, the German government awarded International AIDS Vaccine Initiative (IAVI), worth andeuro;9.2 million, to support the late-stage development of the TB vaccine candidate MTBVAC. This funding, provided by the Federal Ministry of Education and Research (BMBF) through the KfW Development Bank, enabled a collaboration between IAVI, the Spanish biopharmaceutical company Biofabri, and the Netherlands-based Tuberculosis Vaccine Initiative (TBVI) to advance a safe and effective TB vaccine.

Europe Vaccines Market Company Profiles

Some of the key players operating in the market include Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Vaccines Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise